Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Accumulated Expenses (2018 - 2025)

Bicycle Therapeutics' Accumulated Expenses history spans 8 years, with the latest figure at $17.0 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 4.47% year-over-year to $17.0 million; the TTM value through Dec 2025 reached $17.0 million, up 4.47%, while the annual FY2025 figure was $17.0 million, 4.47% up from the prior year.
  • Accumulated Expenses reached $17.0 million in Q4 2025 per BCYC's latest filing, down from $44.4 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $44.4 million in Q3 2025 to a low of $1.7 million in Q1 2021.
  • Average Accumulated Expenses over 5 years is $14.3 million, with a median of $10.4 million recorded in 2021.
  • Peak YoY movement for Accumulated Expenses: tumbled 57.93% in 2023, then skyrocketed 513.02% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $6.4 million in 2021, then surged by 311.45% to $26.5 million in 2022, then plummeted by 49.36% to $13.4 million in 2023, then grew by 21.49% to $16.3 million in 2024, then increased by 4.47% to $17.0 million in 2025.
  • Per Business Quant, the three most recent readings for BCYC's Accumulated Expenses are $17.0 million (Q4 2025), $44.4 million (Q3 2025), and $11.3 million (Q2 2025).